Kissei Pharmaceutical (4547) Q3 2026 earnings summary

Executive summary

• Net sales rose 10.6% year-over-year to ¥72,633 million for the nine months ended December 31, 2025, driven by growth in key pharmaceutical products and expansion in information services and construction segments.

• Despite higher sales, operating and ordinary losses were recorded due to increased cost of sales ratio and higher R&D and SG&A expenses; profit attributable to owners of parent increased 24.6% year-over-year to ¥11,014 million, aided by extraordinary gains from investment securities sales.

• Comprehensive income surged to ¥17,577 million from a loss in the prior year period.

Financial highlights

• Operating loss of ¥3,682 million versus operating profit of ¥4,238 million in the prior year period.

• Ordinary loss of ¥2,226 million compared to ordinary profit of ¥5,298 million year-over-year.

• Extraordinary income of ¥16,000 million, mainly from gain on sale of investment securities.

• Total assets increased to ¥259,607 million, up ¥15,547 million from March 31, 2025.

• Equity ratio declined to 83.4% from 85.6% at the previous fiscal year-end.

Outlook and guidance

• Full-year net sales forecast at ¥95,500 million, up 8.1% year-over-year; profit attributable to owners of parent projected at ¥12,700 million, up 6.2%.

• No change to previously announced financial results forecast.

• Year-end dividend forecast revised to ¥100.00 per share, including a ¥40.00 commemorative dividend for the 80th anniversary.